Movement Alert｜BridgeBio Pharma, Inc. Overnight Decline 7.62%, despite Q3 revenue and loss beating expectations

Market Focus10-30

On October 30, BridgeBio Pharma, Inc. fell 7.62% Overnight, trading at $65.18 per share, with Turnover of $1.34 ten thousand.

The clearest recent catalyst was the company’s latest quarterly report, which showed third-quarter results ahead of analyst expectations even as the stock moved lower in Overnight trading.

BridgeBio Pharma, Inc. reported a Q3 net loss of $0.42 per diluted share, improved from a $0.95 loss a year earlier and better than the expected $0.54 loss. Revenue rose to $353.2 million from $120.7 million a year earlier, also above expectations of $293.5 million. A separate earnings flash likewise highlighted the EPS beat, while another market item noted the shares still declined after the release, indicating that stronger reported figures did not prevent near-term selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment